

See “Trough level of infliximab is useful for assessing mucosal healing in Crohn’s disease: a prospective cohort study” on page 223.

Supplementary Table 2. ATI Positivity in LOR Group and Remission Group by Assay A and Assay B (Study 1)

	LOR group	Remission group	Total
Assay A			
ATI positive	5	2	7
ATI negative	8	2	10
Total	13	4	17
ATI inconclusive	42	49	91
Assay B			
ATI positive	36	17	53
ATI negative	19	36	55
Total	55	53	108

ATI, antibodies to infliximab; LOR, loss of response.